"This time it's not about going back and selling the company!" Drug companies that suffer from waist-slashing price cuts

This is the story that took place on the third day of the health care negotiations, and whether it should be shared or not, the editorial department's small partners have been entangled for days.
the results are not as much of an industry concern as the PD-1 shortlist, but they may also represent the voice of more small and medium-sized enterprises.
"The negotiations failed!" On the afternoon of the final day of the health-care negotiations, the nerves of dozens of media and pharmaceutical company representatives crouching in the cold wind were "activated" by a man who had just finished negotiating out of the scene.
named Wang Haopeng, from Jin Shikang Pharmaceuticals in Xinjiang, came to Beijing from Urumqi with a group of three people.
, of course, is to try to put our only product, rheumatoid Chinese medicine, into the 2021 National Health Insurance Directory.
, chairman of Jinshikang Pharmaceuticals in Xinjiang, china, but the reality is always cruel.
Even with the aura of "Xinjiang's first new drug in a decade to pass certification and have independent intellectual property rights", even if he is already familiar with the negotiation process at the "briefing meeting" of the State Health Insurance Administration pharmaceutical companies, even if he has already copied the bottom price reduction of 60%, Wang Haopeng is still unable to recover the failure of the negotiations.
unlike most delegates who walked out of the talks without a word or a rush, Mr. Wang's blunt answer came as a bit of a surprise when he was surrounded by the media and asked, "Are you satisfied with the outcome of the negotiations?"
may have been too disappointed with the failure of the health-care directory, "a drop of more than 60 per cent that has hit the cost line, but is still 20 per cent higher than the underlying price that the health-care bureau expected."
" reporter seemed to see a thym of tears in his eyes.
Wang Haopeng, who has not yet come out of the shadow of defeat, seems a little excited: "A drug from research and development to market, it will take at least 15-20 years, research and development costs are high and the success rate is very low, if the price is too low, it is difficult for enterprises to survive, how to drive innovation and development?" His words also touched another pharmaceutical company representative who was waiting for the outcome of his own negotiations.
"I recommend opening the way for innovative drugs, leaving three to five years for innovative drugs to adapt to the market before starting to cut prices."
"Wang Haopeng some helplessness, " the drug just listed is low prices or even the floor price, how should enterprises develop? How to innovate after that? Not all companies can continue to innovate research and development without making a profit.
" this year did not be selected, the policy remains unchanged, no matter how many years of sprinting did not use "Wang Haopeng difficult to hide the loss," perhaps this time back can only sell the company.
", perhaps, colder than the December cold wind, is the heart of the "Golden Shikangs".
in Xinjiang, where the pharmaceutical industry is underdeveloped, Jin Shikang was a role model for local new drug manufacturers in Urumqi many years ago.
, Xinjiang Jin Shikang Pharmaceuticals has only one product, for cold dehumidification, for rheumatoid arthritis cold and wet paralysis evidence.
Public information shows that cold dehumidification is an ancestral treatment of rheumatism prescription, the government has supported enterprise research and development, and gave a lot of financial support, so that the drug became the first in Xinjiang in a decade through the former State Food and Drug Administration certification, with independent intellectual property rights of the new drug, research and development enterprises Xinjiang Jin Shikang Pharmaceuticals also by virtue of this drug from the Xinjiang pharmaceutical industry stand out.
, but even so, the survival of pharmaceutical companies is still difficult.
"We only have one product, and local health insurance doesn't come in, so sales are very difficult and basically we have to go to individual clinics."
, research and development costs, production costs are very high, if below our expectations, enterprises will be difficult to survive.
," Wang said.
fact, this year's change in health-care catalog adjustment policy has given innovative drug companies like Jin Shikang Pharmaceuticals a lot of opportunities.
in August this year, the "2020 National Health Insurance Drug Catalog Adjustment Work Programme" and "2020 National Health Insurance Drug Catalog Adjustment Reporting Guidelines" reflect the state to further encourage drug innovation.
Seven categories can be included in the 2020 drug catalog of the scope of the proposed new drugs, in addition to "approved by the State Drug Administration in accordance with the new drug registration application procedures for the listing of drugs (including new active ingredients, new dosage forms), " including "according to the results of clinical trials to the State Drug Administration supplementary application and approval, adaptation, functional treatment and other major changes in the drug."
To this request, the industry generally believes that this reflects the positive role of health insurance in the pharmaceutical industry innovation, not only to encourage innovative drug research and development, while encouraging "old medicine new" improved innovation, for innovative pharmaceutical enterprises, especially local enterprises to provide new opportunities.
In the 2020 National Health Insurance Drug Catalog Adjustment through formal review of the list of declared drugs, the medical insurance catalog of drugs in line with the "January 1, 2015 to August 17, 2020, approved by the State Drug Administration listed new generic drugs" conditions into the health insurance negotiations a total of 171 new drugs, Jin Shikang Pharmaceutical Production of cold and dehumidification is one of them.
the "Health Care Directory" to give faster access to newly approved innovative drugs, especially those with independent intellectual property rights.
", the National Health Insurance Administration said earlier.
sure, this health-care negotiation, which is encouraging innovation, has been much more moderate.
comprehensive this year's health care negotiations on-site situation, the winning enterprise feedback mostly said that not last year's "tough."
compared with the previous move 50% or even 90% of the decline, a number of representatives revealed that the price of their own products in 30-40%, although "meat pain", but "bite your teeth can persist."
industry pointed out that enterprises want to enter health insurance, is bound to reduce prices.
, on the other hand, when innovation and price cuts meet in the health-care negotiations, the health-care bureau will also take into account the general direction of encouraging domestic innovation, and there may be more room for companies to press prices.
When the health care negotiations become an important catalyst for innovative drug release, only after the market quickly into the list of negotiations, after the success of the negotiations with a larger price reduction in exchange for rapid release opportunities, there will be more opportunities to survive.
Based on the current gradually perfect medical insurance negotiation system, innovative drugs in the initial stage of the market with a relatively large price reduction into the health insurance negotiations directory has gradually become the norm, rapidly promote research and development to seize the first-mover advantage and reasonable pricing strategy will become an important factor in the market competition for innovative drugs.
the original title: "This time did not talk about, go back can only sell the company!" "It's been a difficult winter for drug companies that have cut prices by cutting their waists